CVRx, Inc.

NasdaqGS CVRX

CVRx, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -1.48 M

CVRx, Inc. Net Cash Used For Investing Activities is USD -1.48 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -195.01% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

CVRx, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -501.00 K, a 56.21% change year over year.
CVRx, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.14 M, a -53.35% change year over year.
CVRx, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -746.00 K.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: CVRX

CVRx, Inc.

CEO	Mr. Kevin Hykes
IPO Date	June 30, 2021
Location	United States
Headquarters	9201 West Broadway Avenue
Employees	200
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key trends

Past 5 years